Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Distribution Of The Photosensitizer Motexafin Lutetium And Hypoxia In Patients With Malignancies

NCT00087191 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00087191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00087191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Distribution Of The Photosensitizer Motexafin Lutetium And Hypoxia In Patients With Malignancies
Lead sponsor
National Cancer Institute (NCI)
Phase
Not applicable
Overall status
Terminated
Start date
May 31, 2004
Completion date
Not reported
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult primary liver cancer, carcinoma of the appendix, fallopian tube cancer, gastrointestinal stromal tumor, localized extrahepatic bile duct cancer, localized gallbladder cancer, localized gastrointestinal carcinoid tumor, localized resectable adult primary liver cancer, localized unresectable adult primary liver cancer, metastatic gastrointestinal carcinoid tumor, ovarian sarcoma, ovarian stromal cancer, primary peritoneal cavity cancer, recurrent adult primary liver cancer, recurrent adult soft tissue sarcoma, recurrent colon cancer, recurrent extrahepatic bile duct cancer, recurrent gallbladder cancer, recurrent gastric cancer, recurrent gastrointestinal carcinoid tumor, recurrent non-small cell lung cancer, recurrent ovarian epithelial cancer, recurrent ovarian germ cell tumor, recurrent pancreatic cancer, recurrent rectal cancer, recurrent small intestine cancer, recurrent uterine sarcoma, regional gastrointestinal carcinoid tumor, small intestine adenocarcinoma, small intestine leiomyosarcoma, small intestine lymphoma, stage 0 non-small cell lung cancer, stage i adult soft tissue sarcoma, stage i colon cancer, stage i gastric cancer, stage i non-small cell lung cancer, stage i ovarian epithelial cancer, stage i ovarian germ cell tumor, stage i pancreatic cancer, stage i rectal cancer, stage i uterine sarcoma, stage ii adult soft tissue sarcoma, stage ii colon cancer, stage ii gastric cancer, stage ii non-small cell lung cancer, stage ii ovarian epithelial cancer, stage ii ovarian germ cell tumor, stage ii pancreatic cancer, stage ii rectal cancer, stage ii uterine sarcoma, stage iii adult soft tissue sarcoma, stage iii colon cancer, stage iii gastric cancer, stage iii ovarian epithelial cancer, stage iii ovarian germ cell tumor, stage iii pancreatic cancer, stage iii rectal cancer, stage iii uterine sarcoma, stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer, stage iv adult soft tissue sarcoma, stage iv colon cancer, stage iv gastric cancer, stage iv non-small cell lung cancer, stage iv ovarian epithelial cancer, stage iv ovarian germ cell tumor, stage iv pancreatic cancer, stage iv rectal cancer, stage iv uterine sarcoma, unresectable extrahepatic bile duct cancer, unresectable gallbladder cancer